Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3545-3555

  Williams, Emily L ^a   Dunn, Stuart N ^a   James, Sonya ^a   Johnson, Peter W ^a   Cragg, Mark S ^a   Glennie, Martin J ^a   Gray, Juliet C ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CHROMIUM 51; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GLYCYLTRYPTOPHANYLGLUTAMYLASPARTYLPROLYLPROLYLASPARAGINYLASPARTYLISOLEUCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4-1BB; PEPTIDE VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; HYBRIDOMA; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; LONG TERM SURVIVAL; MOUSE; NATURAL KILLER T CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TREATMENT OUTCOME; TUMOR REGRESSION; AMINO ACID SEQUENCE; ANIMAL; CYTOLOGY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MORTALITY; NATURAL KILLER CELL; SPLEEN; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; NEUROBLASTOMA; SPLEEN; VACCINES, SUBUNIT;

EID: 84879874041     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3226     Document Type: Article

References (50)

1. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, EllershawC, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008;9:247-56. (Pubitemid 351722944)
2. Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, et al. Outcomes of the POG9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:747-53.
3. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenancechemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005;6:649-58. (Pubitemid 41222755)
4. Gray JC, Kohler JA. Immunotherapy for neuroblastoma: turning promise into reality. Pediatr Blood Cancer 2009;53:931-40.
5. Martin RF, Beckwith JB. Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance. J Pediatr Surg 1968;3:161-4.
6. Lauder I. Aherne W The significance of lymphocytic infiltration in neuroblastoma. Br J Cancer 1972;26:321-30.
7. Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, et al. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006;24:5725-34. (Pubitemid 46631315)
8. Gray JC, Johnson PW, Glennie MJ. Therapeutic potential of immunostimulatory monoclonal antibodies. Clin Sci 2006;111:93-106. (Pubitemid 44220523)
9. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: costimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 2009;157:9-19.
10. Khalil M, Vonderheide RH. Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther 2007;2:61-65. (Pubitemid 47393664)
11. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010;37:430-9.
12. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5. (Pubitemid 27264981)
13. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 2002;168:2720-8. (Pubitemid 34211649)
14. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6. (Pubitemid 26102823)
15. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96. (Pubitemid 40216472)
16. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
17. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009;15:6446-53.
18. Calabro L, Danielli R, Sigalotti L, Maio M. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 2010;37:460-7.
19. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4371-7.
20. Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, Green MH, et al. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol 2002;32:3617-27. (Pubitemid 36024398)
21. George AJ, McBride HM, Glennie MJ, Smith LJ, Stevenson FK. Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants. Hybridoma 1991;10:219-27.
22. Hasbold J, Johnson-Leger C, Atkins CJ, Clark EA, Klaus GG. Properties of mouse CD40: cellular distribution ofCD40andBcell activation by monoclonal anti-mouse CD40 antibodies. Eur J Immunol 1994;24:1835-42. (Pubitemid 24237554)
23. Cobbold SP, Martin G, Waldmann H. The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunol 1990;20:2747-55.
24. Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003;63:5480-9. (Pubitemid 37139867)
25. Tutt AL, French RR, Illidge TM, Honeychurch J, McBride HM, Penfold CA, et al. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol 1998;161:3176-85. (Pubitemid 28425747)
26. Croce M, Meazza R, Orengo AM, Fabbi M, Borghi M, Ribatti D, et al. Immunotherapy of neuroblastoma by an interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 2008;57:1625-34.
27. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002;109:651-9. (Pubitemid 34204844)
28. Miller RE, Jones J, Le T, Whitmore J, Boiani N, Gliniak B, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002;169:1792-800. (Pubitemid 34857639)
29. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998;91:1706-15. (Pubitemid 28110336)
30. Castriconi R, Dondero A, Cilli M, Ognio E, Pezzolo A, De Giovanni B, et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 2007;56:1733-42. (Pubitemid 47313078)
31. Fest S, Huebener N, Bleeke M, Durmus T, Stermann A, Woehler A, et al. Survivin minigeneDNAvaccination is effective against neuroblastoma. Int J Cancer 2009;125:104-14.
32. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007;25:67-77. (Pubitemid 46423592)
33. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34.
34. Kroczek RA, Mages HW, Hutloff A. Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 2004;16:321-7. (Pubitemid 38595371)
35. Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, et al. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci 2004;1028:69-80. (Pubitemid 40361811)
36. Airoldi I, Lualdi S, Bruno S, Raffaghello L, Occhino M, Gambini C, et al. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. Br J Cancer 2003;88:1527-36. (Pubitemid 36713777)
37. Bennaceur K, Chapman J, Brikci-Nigassa L, Sanhadji K, Touraine JL, Portoukalian J. Dendritic cells dysfunction in tumour environment. Cancer Lett 2008;272:186-96.
38. Walker SR, Redlinger RE Jr, BarksdaleEMJr. Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. J Pediatr Surg 2005;40:244-9.
39. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. Immunol Rev 2003;192:161-80. (Pubitemid 36613331)
40. Yan X, Johnson BD, Orentas RJ. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. J Immunol 2008;181:4621-31.
41. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010;430:199-205.
42. Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, et al. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci 2011;102:324-9.
43. Honma I, Kitamura H, Torigoe T, Takahashi A, Tanaka T, Sato E, et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 2009;58:1801-7.
44. Voskens CJ, Strome SE, Sewell DA. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome. Curr Mol Med 2009;9:683-93.
45. Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest 2010;120:3869-77.
46. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 2005;54:400-6. (Pubitemid 40238934)
47. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 2007;30:227-33. (Pubitemid 46667802)
48. Ponzoni M, Guarnaccia F, Corrias MV, Cornaglia-Ferraris P. Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells. Int J Cancer 1993;55:817-23. (Pubitemid 23354900)
49. Ju SA, Lee SC, Kwon TH, Heo SK, Park SM, Paek HN, et al. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-in filtrating lymphocytes. Immunol Cell Biol 2005;83:344-51.
50. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005;12:1005-16. (Pubitemid 41660676)